Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women.
Postmenopausal osteoporosis is a common clinical entity; its complications represent a significant burden to society. In recent years the choice of therapies available for the treatment of postmenopausal osteoporosis has increased dramatically. There are a number of antiresorptive agents currently available including hormone replacement therapy (HRT), selective estrogen receptor modulators (SERMs), bisphosphonates, and dual action bone agents. It is difficult to truly compare these therapies given the lack of direct head-to head studies. The efficacy of antiresorptive therapies can be assessed in a number of ways including measurement of bone mineral density (BMD), assessment of bone turnover markers, and fracture reduction. Other important factors include ease of administration and consequent patient compliance. This article reviews the currently available antiresorptive agents and their effects on the above outcome measures.
Jordan
Natasha
N
Department of Rheumatology, Connolly Hospital, Dublin, Ireland. natashajordan1@yahoo.co.uk
Barry
Maurice
M
Murphy
Eithne
E
D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D001862:Bone Resorption / Q000517:prevention & control*; D015914:Estrogen Replacement Therapy / Q000379:methods*; D005260:Female; D050723:Fractures, Bone / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*
D050071:Bone Density Conservation Agents